Celltech regroups after Pfizer fallout
Tuesday 02 December 2003
Shares in Celltech jumped yesterday on hopes the biotech company could become a takeover target after it regained the rights to market its most advanced new drug.
Pfizer, the world's largest pharmaceutical group, signalled last month that it would drop the product, a treatment for rheumatoid arthritis codenamed CDP870, unless Celltech agreed to a dramatically lower share of the profits.
Celltech said yesterday that it had refused Pfizer's demands and the partnership would be dissolved by February. The UK group will now decide whether to re-license the drug immediately or to spend an estimated $100m (£58m) conducting the last of the human trials needed.
Celltech, which is believed to have attracted takeover interest from the Swiss biotech group Serono, promised a decision on CDP870's future early in the new year.
Goran Ando, Celltech's chief executive, said he would "start returning calls" from a number of biotech and pharmaceutical companies which had expressed an interest in bankrolling CDP870 since the dispute with Pfizer became public.
Shareholders might be better served by Celltech investing in the further rheumatoid arthritis trials itself, he said. "We generate £50m of cash a year, so we can handle all the permutations," Mr Ando said. Celltech shares rose 23.5p to 375p yesterday.
Mountain goats miraculously survive avalanche in the Alps
Skyfall's Ben Whishaw confirmed for Freddie Mercury film
A cautionary tale for ambitious would-be authors
Trenton Oldfield deportation: Boat Race protester allowed to stay in UK over fears his Indian wife would face racism in Australia
Sir Ian McKellen hits back at Damian Lewis' 'fruity actor' claims
Teenage girl convicted of robbery after taking pre-crime selfie wielding knife
Housing double whammy: A whole generation ‘won’t be able to buy or rent a home’
'I'm experiencing austerity as well', says Princess Michael of Kent
- 1 Gurdwaras-turned-food banks: Sikh temples are catering for rise in Britain’s hungry
- 2 TK Maxx and discount stores: If it looks too good to be true, it probably is
- 3 Teenage girl convicted of robbery after taking pre-crime selfie wielding knife
- 4 Government delays EU immigration report because it is too positive
- 5 'I'm experiencing austerity as well', says Princess Michael of Kent
- < Previous
- Next >
iJobs Money & Business
£75000 - £85000 per annum + attractive benefits: Pro-Recruitment Group: Senior...
£70000 - £80000 per annum + Commission Package: Harrington Starr: Due to winni...
£60000 per annum: Harrington Starr: Support Analyst (Back Office, CRM, Sharepo...
£65000 - £80000 per annum + Excellent Bonus, Package : Harrington Starr: Busin...